Depressant effects of phenoxybenzamine on potassium contracture in cat ventricular muscle

Jay R. Wiggins, Henry Gelband, Arthur L. Bassett

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Phenoxybenzamine has been shown to have a depressant action on K+-depolarization contracture in cat ventricular muscle. In the present study, we show that this depressant action is specific for phenoxybenzamine and occurs in the presence of β-adrenergic receptor blockade with nadolol. K+-contracture is not depressed by phentolamine nor augmented by phenylephrine. Thus, the depressant action of phenoxybenzamine is not mediated by its effects on cardiac adrenergic receptors.

Original languageEnglish
Pages (from-to)111-114
Number of pages4
JournalEuropean Journal of Pharmacology
Volume59
Issue number1-2
DOIs
StatePublished - Oct 26 1979
Externally publishedYes

Fingerprint

Phenoxybenzamine
Contracture
Potassium
Cats
Muscles
Adrenergic Receptors
Nadolol
Phentolamine
Phenylephrine

Keywords

  • Phenoxybenzamine
  • Phentolamine
  • Phenylephrine
  • Potassium contracture
  • Ventricular muscle

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Depressant effects of phenoxybenzamine on potassium contracture in cat ventricular muscle. / Wiggins, Jay R.; Gelband, Henry; Bassett, Arthur L.

In: European Journal of Pharmacology, Vol. 59, No. 1-2, 26.10.1979, p. 111-114.

Research output: Contribution to journalArticle

Wiggins, Jay R. ; Gelband, Henry ; Bassett, Arthur L. / Depressant effects of phenoxybenzamine on potassium contracture in cat ventricular muscle. In: European Journal of Pharmacology. 1979 ; Vol. 59, No. 1-2. pp. 111-114.
@article{83c6b4c5d12941d8b48839e31a81e9db,
title = "Depressant effects of phenoxybenzamine on potassium contracture in cat ventricular muscle",
abstract = "Phenoxybenzamine has been shown to have a depressant action on K+-depolarization contracture in cat ventricular muscle. In the present study, we show that this depressant action is specific for phenoxybenzamine and occurs in the presence of β-adrenergic receptor blockade with nadolol. K+-contracture is not depressed by phentolamine nor augmented by phenylephrine. Thus, the depressant action of phenoxybenzamine is not mediated by its effects on cardiac adrenergic receptors.",
keywords = "Phenoxybenzamine, Phentolamine, Phenylephrine, Potassium contracture, Ventricular muscle",
author = "Wiggins, {Jay R.} and Henry Gelband and Bassett, {Arthur L.}",
year = "1979",
month = "10",
day = "26",
doi = "10.1016/0014-2999(79)90031-1",
language = "English",
volume = "59",
pages = "111--114",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Depressant effects of phenoxybenzamine on potassium contracture in cat ventricular muscle

AU - Wiggins, Jay R.

AU - Gelband, Henry

AU - Bassett, Arthur L.

PY - 1979/10/26

Y1 - 1979/10/26

N2 - Phenoxybenzamine has been shown to have a depressant action on K+-depolarization contracture in cat ventricular muscle. In the present study, we show that this depressant action is specific for phenoxybenzamine and occurs in the presence of β-adrenergic receptor blockade with nadolol. K+-contracture is not depressed by phentolamine nor augmented by phenylephrine. Thus, the depressant action of phenoxybenzamine is not mediated by its effects on cardiac adrenergic receptors.

AB - Phenoxybenzamine has been shown to have a depressant action on K+-depolarization contracture in cat ventricular muscle. In the present study, we show that this depressant action is specific for phenoxybenzamine and occurs in the presence of β-adrenergic receptor blockade with nadolol. K+-contracture is not depressed by phentolamine nor augmented by phenylephrine. Thus, the depressant action of phenoxybenzamine is not mediated by its effects on cardiac adrenergic receptors.

KW - Phenoxybenzamine

KW - Phentolamine

KW - Phenylephrine

KW - Potassium contracture

KW - Ventricular muscle

UR - http://www.scopus.com/inward/record.url?scp=0018652250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018652250&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(79)90031-1

DO - 10.1016/0014-2999(79)90031-1

M3 - Article

C2 - 510392

AN - SCOPUS:0018652250

VL - 59

SP - 111

EP - 114

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-2

ER -